P. de Jong

Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study

D. van Zeben, J. Hazes, H. Xiong, 2018, Scandinavian journal of rheumatology.

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

P. de Jong, M. Verstappen, H. V. van Steenbergen, 2022, Arthritis Research & Therapy.

Arthroscopic synovectomy versus intra-articular injection of corticosteroids for the management of refractory psoriatic or rheumatoid arthritis of the wrist: study protocol for a randomized controlled trial (ARCTIC trial)

N. Schep, M. Kok, A. H. M. van der Helm-van Mil, 2023, Trials.

Cytokine and chemokine gene expression in patients with clinically suspect arthralgia; a longitudinal study during progression to inflammatory arthritis or non-progression

S. V. D. van den Eeden, A. Geluk, E. Lubberts, 2022, medRxiv.

OP0115 Improved response to etanercept is associated with serum vitamin d levels in rheumatoid arthritis

E. Lubberts, S. Heil, J. Hazes, 2018, THURSDAY, 14 JUNE 2018.

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

D. van Zeben, A. Gerards, M. V. van Krugten, 2014, Annals of the rheumatic diseases.

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

D. van Zeben, A. Gerards, J. Luime, 2012, Annals of the rheumatic diseases.

POS0649 WHEN DOES OBESITY EXERT ITS EFFECT IN CONFERRING RISK OF DEVELOPING RA – A LARGE STUDY IN COHORTS OF SYMPTOMATIC PATIENTS AT RISK

P. de Jong, H. V. van Steenbergen, A. Willemze, 2023, Annals of the Rheumatic Diseases.